EVER Pharma GmbH
- Legal form
- GmbH
- Seat
- Gröbenzell, Germany
Based on the notices and sources Inteliwert covers; not a complete record. Last checked 8 July 2026.
Identifiers
As the covered sources state them.
- Register entry
- HRB 215470
Track record in public tenders
Awards in the covered notices over the last 36 months, per CPV division.
No award found in the indexed notices of the last 36 months.
Awards
- Arzneimittelausschreibung 2026_vergebene AufträgeBuyer: IKK classic · Award value: €493,124 excl. VAT · Awarded: 8 July 2026 · CPV 33600000
- Arzneimittelausschreibung 2026_vergebene AufträgeBuyer: IKK classic · Award value: €493,124 excl. VAT · Awarded: 8 July 2026 · CPV 33600000
Certifications and prequalification
No certification or prequalification found in the covered sources.
A certification missing here is unknown, not absent.
Website and LinkedIn
Not found in the indexed notices.
Open tenders that might fit
Possible match based on public information
Companies Inteliwert knows from its sources, not the whole market. Inteliwert does not judge eligibility, fit or chances.
-
OpenTenderSME (from the award notice)
Open-House-Rabattverträge 2026-13 Nintedanib
Reasons
- Won a contract in CPV group 336 (2026-07-08) Evidence · checked 10 Nov 2026
- Seat in the same country as the place of performance Evidence · checked 10 Nov 2026
- 2 awards in this field in 36 months, from 1 buyer Evidence · checked 10 Nov 2026
Last checked 10 Nov 2026, 03:30 (UTC+01:00)Official notice -
OpenTenderSME (from the award notice)
Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130 a Abs. 8 SGB V ab dem 01.09.2026
Reasons
- Won a contract in CPV group 336 (2026-07-08) Evidence · checked 10 Nov 2026
- Seat in the same country as the place of performance Evidence · checked 10 Nov 2026
- 2 awards in this field in 36 months, from 1 buyer Evidence · checked 10 Nov 2026
Last checked 10 Nov 2026, 01:31 (UTC+01:00)Official notice -
OpenTenderSME (from the award notice)
Arzneimittel mit dem Wirkstoff Rasagilin (ATC: N04BD02)
Reasons
- Won a contract in CPV group 336 (2026-07-08) Evidence · checked 10 Nov 2026
- Seat in the same country as the place of performance Evidence · checked 10 Nov 2026
- 2 awards in this field in 36 months, from 1 buyer Evidence · checked 10 Nov 2026
Last checked 10 Nov 2026, 01:31 (UTC+01:00)Official notice -
OpenTenderSME (from the award notice)
Arzneimittel mit dem Wirkstoff Nebivolol (ATC: C07AB12)
Reasons
- Won a contract in CPV group 336 (2026-07-08) Evidence · checked 10 Nov 2026
- Seat in the same country as the place of performance Evidence · checked 10 Nov 2026
- 2 awards in this field in 36 months, from 1 buyer Evidence · checked 10 Nov 2026
Last checked 10 Nov 2026, 01:31 (UTC+01:00)Official notice -
OpenTenderSME (from the award notice)
Arzneimittel mit dem Wirkstoff Atomoxetin (ATC: N06BA09 - in der Darreichungsform Hartkapseln)
Reasons
- Won a contract in CPV group 336 (2026-07-08) Evidence · checked 10 Nov 2026
- Seat in the same country as the place of performance Evidence · checked 10 Nov 2026
- 2 awards in this field in 36 months, from 1 buyer Evidence · checked 10 Nov 2026
Last checked 10 Nov 2026, 01:31 (UTC+01:00)Official notice -
OpenTenderSME (from the award notice)
Arzneimittel mit dem Wirkstoff Naproxen (ATC: M01AE02)
Reasons
- Won a contract in CPV group 336 (2026-07-08) Evidence · checked 10 Nov 2026
- Seat in the same country as the place of performance Evidence · checked 10 Nov 2026
- 2 awards in this field in 36 months, from 1 buyer Evidence · checked 10 Nov 2026
Last checked 10 Nov 2026, 01:31 (UTC+01:00)Official notice -
OpenTenderSME (from the award notice)
Arzneimittel mit dem Wirkstoff Interferon beta-1a (ATC: L03AB07 - zur subkutanen Anwendung)
Reasons
- Won a contract in CPV group 336 (2026-07-08) Evidence · checked 10 Nov 2026
- Seat in the same country as the place of performance Evidence · checked 10 Nov 2026
- 2 awards in this field in 36 months, from 1 buyer Evidence · checked 10 Nov 2026
Last checked 10 Nov 2026, 01:31 (UTC+01:00)Official notice -
OpenTenderSME (from the award notice)
Arzneimittel mit dem Wirkstoff Irbesartan und Hydrochlorothiazid (ATC: C09DA24)
Reasons
- Won a contract in CPV group 336 (2026-07-08) Evidence · checked 10 Nov 2026
- Seat in the same country as the place of performance Evidence · checked 10 Nov 2026
- 2 awards in this field in 36 months, from 1 buyer Evidence · checked 10 Nov 2026
Last checked 10 Nov 2026, 01:31 (UTC+01:00)Official notice -
OpenTenderSME (from the award notice)
Arzneimittel mit dem Wirkstoff Aprepitant (ATC: A04AD12 - in der Darreichungsform Hartkapseln)
Reasons
- Won a contract in CPV group 336 (2026-07-08) Evidence · checked 10 Nov 2026
- Seat in the same country as the place of performance Evidence · checked 10 Nov 2026
- 2 awards in this field in 36 months, from 1 buyer Evidence · checked 10 Nov 2026
Last checked 10 Nov 2026, 01:31 (UTC+01:00)Official notice -
OpenTenderSME (from the award notice)
Arzneimittel mit dem Wirkstoff Entecavir (ATC: J05AF10 - in der Darreichungsform Filmtabletten)
Reasons
- Won a contract in CPV group 336 (2026-07-08) Evidence · checked 10 Nov 2026
- Seat in the same country as the place of performance Evidence · checked 10 Nov 2026
- 2 awards in this field in 36 months, from 1 buyer Evidence · checked 10 Nov 2026
Last checked 10 Nov 2026, 01:31 (UTC+01:00)Official notice
Is this your company?
Send corrections, or ask us to remove the profile, to hello@inteliwert.com. You can also ask that the company never be tagged on LinkedIn.
About this profile
Each fact on this page shows its source: a public notice, an open-data register (GLEIF, Wikidata) or the company’s own website. Inteliwert does not rate companies and does not judge eligibility, fit or chances.
Based on the notices and sources Inteliwert covers; not a complete record.
Last checked 8 July 2026.